INNOVATIVE VISION PRODUCTS, INC. Delaware Office: Moscow Office: 3511 Silverside Road, Suite 105, Ivanovskaya 20, Suite 74, County of New Castle, Moscow 127434 Delaware USA 19810 Russia
[email protected] Tel/Fax: +7 495 977 2387 http://www.innovative-vision-products.com ________________________________________________________________________
The IVP name, company spirit and reputation are based on commitment to the highest standards of science. The company is perhaps best known for its dedication to application of natural dipeptide derivatives in ophthalmology since the beginning of the century. Innovative Vision Products is a Pharmaceutical and Nanotechnology Development Company with a focus on innovative chemical entities, drug delivery systems, and unique medical devices to target specific biomedical applications. Over the last decade IVP has developed a track record in developing these technologies to effectively address the unmet needs of specific diseased populations.
The pharmaceutical development of natural di-peptide derivatives to effectively address degenerative ocular disease is what IVP is best known for.
Founded in the year (1998) by Mark Babizhayev MA, PhD, Innovative Vision Products is headquartered in County of New Castle, Delaware. Since its creation IVP has maintained its standards for a higher level of scientific efficacy and has succeeded in developing its impressive portfolio
1
of cutting edge intellectual properties for seamless commercial receptivity and applications.
We establish Partnering and Licencing relations with International Pharmaceutical and Nanotechnology Companies based on the assets in Intellectual Property created by IVP.
Dealmaking in the pharmaceutical and biotechnological industries : covers a wide variety of agreements between individuals, companies and institutions from simple late-stage product 2
acquisitions (deals relating to products in clinical development, approval, launch and marketing) through to complex discovery and focused target Research and Development deals.
Pharma companies are working on the licencing model to increase efficiency, and reduce lead time in drug discovery. The various in-house and outsourced departments function as horizontally and vertically linked networks.
The industry was founded around innovative drug discovery and development. The reality now is that most of the major companies sell about 50 percent of products discovered by companies or institutions other than themselves. And the existing business model of large 3
pharmaceutical companies is such that they are almost forced to go outside and look at in-licensing and acquisition to bolster their development and commercial pipelines.
Some of the large companies have little in their pipelines for the next five years, so they really have very little choice other than acquiring new drugs and compounds. Companies have now become so good at commercialization that some are prepared to take commercial risk but don’t want to take any scientific risk. This has led to a shift in companies’ business models. In the networked R&D model, the licencing company has the liberty to choose the right product at the right price. Early target identification and validation will save considerable time and reduce the risk of last stage failures. Collaborative R&D gives pharma companies a broader product pipeline with stronger and wider therapeutic focus.
4
Licencing deals will become the largest drivers for big pharmaceutical companies by 2010, and by 2005-2010 almost 50% of revenues in major pharma will emerge from licenced compounds by 2005-2010.
Pharma companies are focusing on forward integration, targeted treatment solutions , and biotech drugs for growth in the long time.
5
IVP Achievements We recently announced the official registered release of a newly ophthalmic patented molecule. This molecule is the acetylated (fatty acid/lipophilic) version of L-Carnosine.
6
www.can-c.net www.N-acetylcarnosine.com www.bionational.com www.antiaging-systems.com www.wisechoicemedicine.com
7
We are pleased to inform you that our worldwide patented Product N-acetylcarnosine eye drops is officially registered in all countries of the EU as the CE marked Medical Device Product . The EC certificate was released by the Italian Ministry of Health. This is the certificate that allows the manufacturer to put such a product in commerce in ALL the E.U. countries .
This certificate is called " APPROVAL OF QUALITY ASSURANCE SYSTEM FOR PRODUCTION AND/OR STERILIZATION" and it states that the quality assurance system for the production of Clarastill (patented N-acetylcarnosine eye drops containing carboxymethylcellulose) is in accordance with the requirements of the EC Directive 93/42/CEE; this certificate has a number 099-QPS-206 of 28/12/2006 and states that the registration has a number 0373 . IVP warrants the strong anti-cataract activity of the IVP approved brands of N-acetylcarnosine lubricant eye drops , including Clarastill product, its ability to restore the lens clarity (dissolve cataracts) if the primary Visual Acuity in the human eye with cataract is better than 20/70. Left image: Ripe age-related human cataract before treatment, Male 66 yrs. Right image : Cataract is partially reversed and prevented (rose reflex appears from the fundus ). The same human crystalline lens of a patient becomes significantly more transparent in cortical layers after 9 months of topical treatment with IVP approved brand of N-acetylcarnosine lubricant eye drops (instillations twice daily).
8
Nanoscience and nanotechnology
refer to IVP research at the atomic, molecular or macromolecular levels, at the length scale of approximately within 250 angstrom - 100 nanometers. Pharma companies are considering the use of nanotechnology to augment the value of an original invention. Nanotechnologies help improve drug delivery, and extend the life of the drug. They facilitate medical care tailored explicitly and exactly to the individual. Pharma companies spent close to USD 3 billion on nanotechnology in 2004.
9
A substantial amount of time has been devoted at IVP to technologies being developed and practiced for producing nanostructured materials and devices.
Within a vacuum chamber, metals are bombarded with argon ions. The sputtered metal vapour then partially condenses on the substrate to be coated, forming a thin layer. If one adds a reactive gas in the chamber, then oxide, nitride or carbide layers can be formed.
COATED WITH NANOMATERIALS INTRAOCULAR LENSES, OPHTHALMIC AND HUMAN BODY IMPLANTABLE DEVICES WITH HIGH CATALYTIC ANTIOXIDANT ACTIVITY : A NEW STRATEGY OF PEROXIDASE NATURAL CELLULAR ENZYME MIMICS INCREASING THE BIOCOMPATIBILITY OF THE MEDICAL PROSTHETIC DEVICE
We propose for collaborative implementation and business development/marketing the catalytic antioxidant coatings for 10
the implantable devices including Intraocular Lenses according to the patented by Innovative Vision Products, Inc. in the US technology (US Patent 6,613,088B1) .
This creates the ANTIOXIDANT activites of the intraocular lens for cataract surgery and enables to manage and prevent complications of cataract surgery: intraocular inflammation, secondary cataract, vitreous opacities, corneal swelling, retinal detachment, glare effects , macular oedema .
11
We can coat the Intraocular Lenses and implantable devices of any desired design.
Glaucoma drainage valves
Coated implantable devices are endowed with the better biocompatibility and mimic the activities of the important antioxidant enzymes significant for the tissue and cellular metabolism , repair and the biological surface interactions.
The technology offers physicians and surgeons to develop and commercialize cost-effective medical implantable devices, Products and support systems with metabolic activities for the treatment of ophthalmic diseases and of a wide range of 12
pathological states and disorders which are treated by insertion of the implantable and prosthetic (polymeric) devices . IVP modules are devoted to different industrial sectors including chemicals and cosmetics, energy, electronics and biotechnology/pharmaceutical. The objective is to provide the necessary background in this developing interdisciplinary field so they can be utilized by scientists, engineers and professional managers in a variety of industries including chemicals, energy, environmental, electronics, consumer products, cosmetics, medical devices and pharmaceuticals.
Scanning electron Microscopy Studies
13
Scanning electron microscopy image of single crystal nanospheres of Ti-doped CeO2 nanoparticles. (b) Transmission electron microscopy image of a single crystal CeO2 nanosphere enclosed by a thin shell of amorphous TiO2. (c) Molecular dynamic simulated structure of Ti doped CeO2 nanosphere.
"These spherical, single-crystal Ti-doped CeO2 nanoparticles reduce CMP defects by 80% and increase the silica removal rate by 50%, which will facilitate precise and reliable mass-manufacturing of chips for microelectronics and nanoelectronics," ZL Wang of Georgia Institute of Technology, Peking University, China, and the National Center for Nanoscience and Technology, China, told.
14
BUSINESS INITIATIVE DIRECTIONS
The purpose of this initiative at IVP is to stimulate cross-cutting, integrative research in the nanoapplications fields of science and technology.
In particular, this initiative invites research on: i) the creation and use of structures, devices and systems that have novel properties and functions because of their small size, that may be used to achieve a fundamental understanding of biological processes and /or contribute to disease detection, therapy, or prevention; ii) conception and fabrication of devices, that will effectively detect and analyze nanoscale entities of relevance to biomedicine; and iii) the study of biological systems at the nanoscale for the explicit purpose of using that information to develop nanotechnologies and nanostructured materials that will in turn benefit biology , medicine and Pharmaceutical sciences.
15
A team has been created, Team AFNP, which has laid the foundation of a programme to develop a nanotechnology based system to reduce the risks of tobacco smoke .
The cooperation team of IVP with QinetiQ Nanomaterials has created and proposes for marketing nanoparticles constructed of alloys developed by IVP stabilized from corrosion and oxidation in the thin films endowed with significant anti-bacterial properties for application in several industries including polymeric Packaging, Sterile fill, Food processing , Automotive industries.
16
Anti-bacterial Nano-powders
Anti-bacterial coatings developed by IVP
17
Automotive industry
IVP Mission Applying Innovative Chemistry, IVP develops novel, target specific treatments to improve patient care and address unmet medical needs.
18
Peptide Technologies
Ophthalmic Research at IVP :
19
Lens Research
Glaucoma Research
20
Strategy
IVP patents and licences-out its pipeline products and proprietary Technologies to advance them through regulatory approval.
21
22
We propose to your Organization to consider the cooperation with our Company.
The following large range of services can be discussed and chosen to the best business expectations of our Companies. • • • • • •
•
Product formulation Safety and stability testing Clinical testing Brand image development Contract manufacturing Physician and university endorsements Worldwide distribution
• • • • • • •
Formulation enhancement Clinical protocols Technology licensing Package development Market planning International product registration Infomercial product development
23
Type of business relationship sought
• • • • • • • • • • • • •
Joint Venture Agreement License Agreement Joint further development Testing of new applications Transfer of knowledge in new raw materials New way to use an existing production line Change in the partner sought's currently used technologies (installations, process, facilities) Absolutely novel process Assembly Engineering Technical consultancy Quality control Maintenance
24
Innovative Vision Products Inc. intends to out-license its products at appropriate stages to international pharmaceutical companies, to take its products through late stage clinical studies and assessment by regulatory authorities, in order to get market approval in Western markets.
25
In today’s competitive environment, alliances are critical for pharmaceutical companies to optimize R&D and marketing synergies and share risks in order to develop pipelines. Companies may desire to maximize their licensing and alliance management capabilities in order to bring new drugs to the market successfully, while minimizing the potential for failure.
Respectfully submitted,
Cordially, Dr. Mark A. Babizhayev, Ph.D., Executive Director
Innovative Vision Products, Inc.
26
Delaware Office :
3511 Silverside Road, Suite 105, County of New Castle, Delaware USA 19810; e-mail:
[email protected] Moscow Office : Ivanovskaya 20, Suite 74 Moscow 127434 Russian Federation e-mail:
[email protected] Tel/Fax: +7(495)977-2387 http://www.innovative-vision-products.com
27
28
